Lipid Disorder Treatment Market Report, Global, 2024

The lipid disorder treatment market size has grown rapidly in recent years. It will grow from $9.48 billion in 2023 to $10.69 billion in 2024 at a compound annual growth rate (CAGR) of 12.7%. The growth in the historic period can be attributed to increase in adoption of sedentary lifestyle, rise in working population, rise in awareness regarding the disease and treatment, increase in on-the-desk jobs, growth of familial combined hyperlipidemia incidence.

The lipid disorder treatment market size is expected to see rapid growth in the next few years. It will grow to $17.36 billion in 2028 at a compound annual growth rate (CAGR) of 12.9%. The projected growth in the forecast period can be attributed to several factors, including the increasing cases of obesity and high cholesterol, the rise in the prevalence of cardiovascular diseases, and the growing occurrence of high cholesterol leading to heart diseases. Additionally, there is an escalating demand for safe and efficient treatments, spurred by factors such as excessive alcohol consumption and smoking. Key trends anticipated in the forecast period encompass technological advancements in drug development, product innovation, increased investments in business expansion, advancements in treatment facilities, and clinical advancements. These trends are expected to further drive the growth of the lipid disorder treatment market, catering to the evolving needs of patients and healthcare providers alike.

The anticipated growth in the lipid disorder treatment market is expected to be propelled by the increasing prevalence of obesity and high cholesterol. Obesity, characterized by excessive body fat accumulation, and high cholesterol, denoting elevated cholesterol levels in the blood, pose significant health risks and are on the rise due to various factors including unhealthy diets, sedentary lifestyles, genetic predispositions, and environmental influences. Lipid disorder treatment plays a crucial role in managing obesity and high cholesterol by employing pharmacological interventions alongside lifestyle modifications, weight management strategies, patient education, and multidisciplinary care. For instance, according to the World Obesity Atlas 2022 published by the World Obesity Federation, it is projected that by 2030, one billion people globally will be living with obesity, with that number escalating to 4 billion people, or 51% of the global population, by 2035. Hence, the escalating cases of obesity and high cholesterol are key drivers fueling the growth of the lipid disorder treatment market.

Major companies in this market are focusing on developing innovative therapies to address the need for more effective and targeted treatments for managing high cholesterol levels. One such example is the development of proprotein convertase subtilisin type 9 (PCSK9) inhibitors, which enhance the removal of LDL cholesterol from the bloodstream, thus reducing the risk of cardiovascular events in high-risk patients. For instance, in March 2024, Regeneron Pharmaceuticals Inc. received FDA approval for Praluent (alirocumab) injection to treat heterozygous familial hypercholesterolemia (HeFH) in children aged 8 and above. This medication blocks the binding of PCSK9 to the LDL receptor, increasing the quantity of LDL receptors on liver cell surfaces and facilitating the clearance of LDL cholesterol from the bloodstream.

In July 2023, Eli Lilly and Company's acquisition of Versanis contribute to bolstering companies' portfolios in the cardiometabolic disease space, particularly in the obesity drug pipeline. Versanis, a clinical-stage biopharmaceutical company specializing in treating cardiometabolic diseases, enhances Lilly's capabilities in addressing the challenges posed by obesity and related disorders.

Major companies operating in the lipid disorder treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., AstraZeneca Plc, Fresenius SE & Co. KGaA, Abbott Laboratories Inc., Novartis AG, GlaxoSmithKline Plc, Wockhardt Ltd., Eli Lilly and Company, Amgen Inc., Boehringer-Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Kaneka Corporation, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Emcure Pharmaceuticals Limited, Kowa Pharmaceuticals America Inc., Concord Biotech Limited, Biocon Ltd., Ranbaxy Laboratories Limited.

North America was the largest region in the lipid disorder treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lipid disorder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lipid disorder treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Lipid disorder treatment encompasses a holistic approach involving lifestyle adjustments, medications, and regular monitoring to manage conditions such as high cholesterol and triglycerides. The goal is to mitigate the risk of atherosclerosis and its associated complications, including heart disease and stroke.

Key medications used in lipid disorder treatment include atorvastatin, fluvastatin, rosuvastatin, simvastatin, pravastatin, and others. Atorvastatin, classified as an HMG-CoA reductase inhibitor, is utilized for various lipid disorders, including familial combined hyperlipidemia, familial defective apolipoprotein B-100, familial dysbetalipoproteinemia, familial hypertriglyceridemia, heterozygous familial hypercholesterolemia, among others. This medication is made available through multiple channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others.

The lipid disorder treatment market research report is one of a series of new reports that provides lipid disorder treatment market statistics, including lipid disorder treatment industry global market size, regional shares, competitors with a lipid disorder treatment market share, detailed lipid disorder treatment market segments, market trends and opportunities, and any further data you may need to thrive in the lipid disorder treatment industry. This lipid disorder treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lipid disorder treatment market consists of revenues earned by entities by providing services such as medical consultations, diagnostic tests, lifestyle counseling, medication management, and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The lipid disorder treatment market also includes sales of fibrates, niacin, bile acid sequestrants and omega-3 fatty acids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.